Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence

被引：51

作者：

Daien, Vincent ^{[1
,2
]}

Finger, Robert P. ^{[3
]}

Talks, James S. ^{[4
]}

Mitchell, Paul ^{[5
]}

Wong, Tien Y. ^{[6
,7
]}

Sakamoto, Taiji ^{[8
]}

Eldem, Bora M. ^{[9
]}

Korobelnik, Jean-Francois ^{[10
,11
]}

机构：

[1] Gui Chauliac Hosp, Dept Ophthalmol, Montpellier, France

[2] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia

[3] Univ Bonn, Dept Ophthalmol, Bonn, Germany

[4] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England

[5] Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia

[6] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore

[7] Duke NUS Med Sch, Singapore, Singapore

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima, Japan

[9] Hacettepe Univ, Ophthalmol Dept, Fac Med, Ankara, Turkey

[10] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France

[11] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Talence, France

来源：

BRITISH JOURNAL OF OPHTHALMOLOGY | 2021年 / 105卷 / 11期

关键词：

Epidemiology; Macula; Neovascularisation; Retina; Vision; VISUAL-ACUITY OUTCOMES; GROWTH-FACTOR THERAPY; EXTEND INTRAVITREAL THERAPY; ANTI-VEGF TREATMENT; 2-YEAR OUTCOMES; CHOROIDAL NEOVASCULARIZATION; BASE-LINE; AFLIBERCEPT; RANIBIZUMAB; REGIMEN;

D O I：

10.1136/bjophthalmol-2020-317434

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The aim of this work was to evaluate the contribution of real-world evidence (RWE) in changing anti-vascular endothelial growth factor (VEGF) therapy treatment practices and improving real-world treatment strategies for neovascular age-related macular degeneration (nAMD). A PubMed literature search was performed to review the large number of English-language studies conducted to investigate the real-world effectiveness of anti-VEGF (aflibercept and ranibizumab) treatment paradigms available for nAMD. The evidence for pro re nata (PRN), treat-and-extend (T&E) and fixed bimonthly dosing regimens for anti-VEGF treatment of nAMD were reviewed and findings are summarised. RWE demonstrated that T&E regimens optimise visual outcomes while reducing burden on patients, clinics and physicians, compared with both fixed-dose and PRN regimens. RWE has helped to develop and improve real-world treatment strategies in nAMD, with the aim of optimising visual outcomes and reducing treatment burden in clinical practice. Of the various regimens, a T&E regimen is most likely to adequately balance clinical outcomes and treatment burden for patients with nAMD.

引用

页码：1475 / 1479

页数：5

共 83 条

[1] ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Treat-and-Extend Protocol Over 2 Years [J].